These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29624474)

  • 1. Cationic pullulan nanogel as a safe and effective nasal vaccine delivery system for respiratory infectious diseases.
    Nakahashi-Ouchida R; Yuki Y; Kiyono H
    Hum Vaccin Immunother; 2018; 14(9):2189-2193. PubMed ID: 29624474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a nanogel-based nasal vaccine as a novel antigen delivery system.
    Nakahashi-Ouchida R; Yuki Y; Kiyono H
    Expert Rev Vaccines; 2017 Dec; 16(12):1231-1240. PubMed ID: 29053938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanogel-based antigen-delivery system for nasal vaccines.
    Yuki Y; Nochi T; Kong IG; Takahashi H; Sawada S; Akiyoshi K; Kiyono H
    Biotechnol Genet Eng Rev; 2013; 29():61-72. PubMed ID: 24568253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques.
    Fukuyama Y; Yuki Y; Katakai Y; Harada N; Takahashi H; Takeda S; Mejima M; Joo S; Kurokawa S; Sawada S; Shibata H; Park EJ; Fujihashi K; Briles DE; Yasutomi Y; Tsukada H; Akiyoshi K; Kiyono H
    Mucosal Immunol; 2015 Sep; 8(5):1144-53. PubMed ID: 25669148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines.
    Nochi T; Yuki Y; Takahashi H; Sawada S; Mejima M; Kohda T; Harada N; Kong IG; Sato A; Kataoka N; Tokuhara D; Kurokawa S; Takahashi Y; Tsukada H; Kozaki S; Akiyoshi K; Kiyono H
    Nat Mater; 2010 Jul; 9(7):572-8. PubMed ID: 20562880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal vaccines: solutions for respiratory infectious diseases.
    Nakahashi-Ouchida R; Fujihashi K; Kurashima Y; Yuki Y; Kiyono H
    Trends Mol Med; 2023 Feb; 29(2):124-140. PubMed ID: 36435633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution assessment of cationic pullulan nanogel, a nasal vaccine delivery system, in mice and non-human primates.
    Yuki Y; Harada N; Sawada SI; Uchida Y; Nakahashi-Ouchida R; Mori H; Yamanoue T; Machita T; Kanazawa M; Fukumoto D; Ohba H; Miyazaki T; Akiyoshi K; Fujihashi K; Kiyono H
    Vaccine; 2023 Jul; 41(34):4941-4949. PubMed ID: 37385890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upper respiratory tract immunity.
    Zuercher AW
    Viral Immunol; 2003; 16(3):279-89. PubMed ID: 14583144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?
    Marasini N; Kaminskas LM
    Drug Dev Ind Pharm; 2019 Jun; 45(6):882-894. PubMed ID: 30767591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal Lactobacillus vectored vaccines.
    Yu Q; Zhu L; Kang H; Yang Q
    Hum Vaccin Immunother; 2013 Apr; 9(4):805-7. PubMed ID: 23322214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic-nanogel nasal vaccine containing the ectodomain of RSV-small hydrophobic protein induces protective immunity in rodents.
    Umemoto S; Nakahashi-Ouchida R; Yuki Y; Kurokawa S; Machita T; Uchida Y; Mori H; Yamanoue T; Shibata T; Sawada SI; Ishige K; Hirano T; Fujihashi K; Akiyoshi K; Kurashima Y; Tokuhara D; Ernst PB; Suzuki M; Kiyono H
    NPJ Vaccines; 2023 Jul; 8(1):106. PubMed ID: 37488116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways.
    Li M; Zhao M; Fu Y; Li Y; Gong T; Zhang Z; Sun X
    J Control Release; 2016 Apr; 228():9-19. PubMed ID: 26941035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Craniofacial mucosal immune system: importance of its unique organogenesis and function in the development of a mucosal vaccine.
    Okada K; Yamasoba T; Kiyono H
    Adv Otorhinolaryngol; 2011; 72():31-6. PubMed ID: 21865684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mucosal immune system for vaccine development.
    Lamichhane A; Azegamia T; Kiyonoa H
    Vaccine; 2014 Nov; 32(49):6711-23. PubMed ID: 25454857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles for nasal vaccination.
    Csaba N; Garcia-Fuentes M; Alonso MJ
    Adv Drug Deliv Rev; 2009 Feb; 61(2):140-57. PubMed ID: 19121350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity.
    Rochereau N; Pavot V; Verrier B; Jospin F; Ensinas A; Genin C; Corthésy B; Paul S
    J Allergy Clin Immunol; 2016 Jan; 137(1):214-222.e2. PubMed ID: 26414879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanogel-based nasal vaccines for infectious and lifestyle-related diseases.
    Azegami T; Yuki Y; Nakahashi R; Itoh H; Kiyono H
    Mol Immunol; 2018 Jun; 98():19-24. PubMed ID: 29096936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.
    Hodge LM; Marinaro M; Jones HP; McGhee JR; Kiyono H; Simecka JW
    Infect Immun; 2001 Apr; 69(4):2328-38. PubMed ID: 11254590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.